Palatin Technologies, Inc. · AMEX:PTN
Palatin Technologies — Investor Presentation (November 2025)
68 slides from Palatin Technologies's investor presentation, November 2025
Slide 1: Palatin Technologies Corporate Presentation
Palatin Technologies, Inc. NYSE American: PTN CORPORATE PRESENTATION November 2025 Carl Spana, Ph.D. Stephen T. Wills, CPA/MST President & CEO CFO / COO
Slide 2: Forward Looking Statements
Forward Looking Statements The statements in this presentation that relate to future plans, events or performance are forward-looking statements, which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended. Such forward-looking statements involve si
Slide 3: Company Profile
Company Profile Technology platform – validated drug development based on the melanocortin system Therapeutics for Obesity, Inflammatory & Autoimmune Diseases Demonstrated expertise moving programs from discovery to FDA approval Expertise in the biology and chemistry of melanocortin system (MCS) 1st
Slide 4: Palatin Leadership
Palatin Leadership Strong team, with broad and extensive biopharma experience Stephen T. Wills, CPA/MST Carl Spana, PhD Chief Financial Officer and President and Chief Executive Officer Chief Operating Officer Co-founder with 25-plus years in drug 25-plus years in finance, operations, research, deve
Slide 5: Development Programs Overview
Development Programs Overview Pipeline Development Programs Preclinical Phase 1 Phase 2 Phase 3 NDA Status/Next Steps Obesity Bremelanotide Phase 2 MC4R agonist + GLP-1 in obese patients initiated Obesity - GLP-1 adjunct therapy Positive topline data reported 1Q25 Proof-of-concept study only PL7737
Slide 6: Melanocortin-4 Receptor Obesity Management: Emerging obesity treatment landscape
Melanocortin-4 Receptor Obesity Management Emerging obesity treatment landscape U.S. market value – metabolic/obesity over $5 billion (2023) growing to $44 Billion (2030) Two treatment objectives will define the market • Safe, tolerable weight loss for all patients • Central Leptin-Melanocortin path
Slide 7: Review of weight loss maintenance
Melanocortin-4 Receptor Obesity Management Review of weight loss maintenance Realizing the long-term benefits of obesity treatment Excess body weight and fat is associated with Including cardiovascular disease, diabetes, fatty liver disease, negative health conditions musculoskeletal disorders and s
Slide 8: The melanocortin receptor system: obesity and energy management
C o n Melanocortin-4 Receptor Obesity Management f The melanocortin receptor system: obesity and energy management i d e n t i a l Central leptin-melanocortin pathway is a critical pathway that regulates feeding and body weight to maintain energy homoeostasis 8 Sweeney, P et.al. Nature Reviews Endoc
Slide 9: Value of Palatin's MC4R agonist portfolio
Melanocortin-4 Receptor Obesity Management Value of Palatin’s MC4R agonist portfolio New mechanisms will be Clinically validated Novel improved “Next Gen” required for obesity therapy Bremelanotide treatment for obesity Selective MC4R agonists and weight loss maintenance Obesity therapy will require
Slide 10: Melanocortin-4 Receptor Obesity Management
Melanocortin-4 Receptor Obesity Management • Bremelanotide MC4R agonist Phase 1b clinical weight loss study in general obese subjects • Co-administration of Bremelanotide MC4R & Tirzepatide (GLP-1/GIP) o Bremelanotide (BMT) MC4R Agonist ✓ FDA Approved (Vyleesi® for Female HSDD)
Slide 11: Bremelanotide Phase 1b weight loss study
C o n Melanocortin-4 Receptor Obesity Management f i Bremelanotide MC4R agonist obesity Phase 1b clinical weight loss study in general obese subjects d e n 2-Week Study t i • General obese subjects: BMI ~35 a o Bremelanotide: n=27 l o Vehicle: n=26 • Weight loss: o Placebo -0.7kg; Bremelanotide: -2.
Slide 12: GLP-1/GIP agonist + MC4R agonist co-administration clinical data
Melanocortin-4 Receptor Obesity Management GLP-1/GIP agonist + MC4R agonist: co-administration clinical data* • No prospective studies have been done with combination pharmacotherapy • Previously published combination of setmelanotide plus 2.5mg of tirzepatide for obesity in BBS • 2 patients lost 26
Slide 13: BMT-801 signal detection study objectives
Melanocortin-4 Receptor Obesity Management BMT-801 Phase 2 signal detection study objectives Co-Administration GLP1/GIP Agonist Tirzepatide (2.5mg Weekly) + MC4R Agonist Bremelanotide (1.25mg Daily) Main Research Questions • Does co-administration result in increased weight loss? • Does MC4R agonism
Slide 14: BMT-801 study design
Melanocortin-4 Receptor Obesity Management BMT-801 Phase 2 signal detection study Co-Administration GLP1/GIP Agonist Tirzepatide & MC4R Agonist Bremelanotide Study Design: Randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of the addition of an MC4R agonist (BMT) t
Slide 15: BMT-801 patient weight loss from baseline
Melanocortin-4 Receptor Obesity Management BMT-801 patient weight loss from baseline to end of study Primary Endpoint – Co-Administration Group Greatest Weight Loss Patient Weight Change (%) from Baseline to End of Study Compared to PBO Patient Weight Change (%) from Baseline to End of Study Compare
Slide 16: Co-administration additive effect – primary analysis
Melanocortin-4 Receptor Obesity Management Co-administration additive effect – primary analysis Analysis for Additive Effect Percent of Subjects with ≥4% Reduction in Percent Weight Loss at End of Study 60 Group 1 Group 2 Group 3 Group 4 Group 1: Tirzepatide (2.5 mg SC) weekly/BMT (1.25 mg SC) daily
Slide 17: Effect of co-administration on increased weight loss
Melanocortin-4 Receptor Obesity Management Effect of co-administration on increased weight loss Weekly Change in Percent Body Weight (%) by Group 0 -0.5 • Comparison of Group 4 to Group 3 -1 during Treatment Period 2 demonstrates a weight loss Percent Change in % Weight -1.5 maintenance effect -2 -2
Slide 18: BMT-801 study questions and outcomes
Melanocortin-4 Receptor Obesity Management BMT-801 Phase 2 signal detection study questions / outcomes Co-Administration GLP1/GIP Agonist Tirzepatide (2.5mg Weekly) + MC4R Agonist Bremelanotide (1.25mg Daily) Main Research Questions Main Study Outcomes 1. Does co-administration result in increased 1
Slide 19: Value of study results and next steps
Melanocortin-4 Receptor Obesity Management BMT-801 MC4R/GLP-1-GIP co-administration detection study Value of the study results and next steps Confirmation that MC4R treatment with GLP-1/GIP can be additive without increasing safety and BMT-801 Study tolerability issues Support to perform co-administ
Slide 20: Novel Next Generation MC4R Selective Agonists
Melanocortin-4 Receptor Obesity Management • Novel “Next Generation” MC4R Selective Agonists o PL7737 Oral MC4R Selective Small Molecule o MC4R Selective Peptides Once Weekly Dosing
Slide 21: Obesity focused development programs
Novel "Next Generation" Selective MC4R Agonists Obesity focused development programs Multiple clinical trials targeted in 2026 with novel MC4R compounds for treating syndromic and genetic obesity such as hypothalamic obesity. Product/Indication R&D Phase 1 Phase 2 Phase 3 NDA Status/Next Steps Breme
Slide 22: MC4R selective oral small molecule program
The Melanocortin-4 Receptor Obesity Program MC4R selective oral small molecule program: pathway for obesity management Current Therapy Challenges Palatin Achieved Solutions Injection Frequency Palatin identified small molecules show excellent preclinical oral bioavailability. Palatin small molecules
Slide 23: Understanding what is required for success
The Melanocortin-4 Receptor Obesity Program Novel “next generation” MC4R selective agonists: understanding what is required for success Historically, MC4R small molecule programs have failed due to a lack of understanding the receptor biology and the structure/function relationship that determine we
Slide 24: Ideal PK profile for an obesity treatment
The Melanocortin-4 Receptor Obesity Program Ideal PK profile for an obesity treatment (PK consistency across mouse, rat, dog) • Oral drug delivery • Protein binding facilitates efficacious levels without surpassing them • PL7737 does not have a high transient Cmax helps to avoid AE’s • Once per day
Slide 25: PL7737 preclinical data highlights
PL7737 Oral MC4R Agonist Preclinical data highlights / 4-Day Diet-Induced Obese (DIO) Rat Study Treatment Arm Weight Loss (% after 4 days) ➢ Rapid, dose-dependent weight loss PL7737 – Middle Dose 5% ➢ PL7737 monotherapy produced PL7737 – High Dose 10% • Rapid and significant weight loss after just 4
Slide 26: PL7737 and tirzepatide in DIO rats
Novel "Next Generation" Selective MC4R Agonists PL7737 and tirzepatide: oral PL7737 causes significant weight loss in diet-induced obesity (DIO) rats • PL7737 dosed orally at 3, 10 and 30mg/kg • PL7737 at 10 and 30mg/kg doses caused significant weight loss in DIO rats • PL7737 + Tirzepatide - additi
Slide 27: Current/Planned activities for PL7737
The Melanocortin-4 Receptor Obesity Program Current/Planned activities for PL7737 IND-enabling toxicology activities started •Toxicology studies ongoing •IND planned for submission in 1H 2026 CMC activities ongoing •Non-GMP tox API being manufactured •GMP clinical API manufacture initiated •Phase 1/
Slide 28: Next Generation MC4R Selective Peptide Agonists
Novel "Next Generation" MC4R Selective Peptide Agonists The melanocortin receptor system Legacy challenges of MC4R agonists have been solved. Current Therapy Challenges Palatin Achieved Solutions Palatin’s compounds with high potency coupled with structural Injection Frequency elements, extend drug
Slide 29: Next generation MC4R peptide agonist series
Novel "Next Generation" MC4R Selective Peptide Agonists First series of ‘next generation’ MC4R peptide agonists for obesity: • Palatin studies in MC4R knock-out model confirm weight loss is dependent on a functional MC4R • PL8905 potential lead development candidate o Selective MC4R agonist: Signifi
Slide 30: Long-acting once weekly peptide activities
Novel "Next Generation“ MC4R Selective Peptide Agonists Current/Planned activities – long-acting once weekly administration SC peptides Highly selective MC4R agonsits to avoid hyperpigmentation, no blood pressure effects and enabling once weekly injection into one compound accomplished •Multiple can
Slide 31: Hypothalamic Obesity (HO)
Hypothalamic Obesity (HO)
Slide 32: Hypothalamic Obesity overview
Hypothalamic Obesity (HO) A rare, form of obesity following injury to the hypothalmus region Acquired HO Craniopharyngioma are brain tumors that develop near the hypothalamus and pituitary gland Treatments include tumor resection surgery, radiation or both Treatment damages the hypothalamus leading
Slide 33: Next generation melanocortin agonists for HO
Hypothalamic Obesity (HO) Palatin’s next generation melanocortin agonists for the advanced treatment of HO ✓ Unmet medical need is high; no approved 5,000 – 10,000** patients therapies Estimated U.S. prevalence ✓ MC4R pathway deficiency following injury to hypothalamic region ✓ Patients are easily i
Slide 34: Significant opportunity in Japan
Hypothalamic Obesity (HO) Significant opportunity in Japan i.e., higher per-capita incidence and prevalence of HO • Prevalence in Japan is approximately 2X higher than in the USA & Europe due to a higher frequency of craniopharyngioma o Could be genetic or environmental • > 100 health care centers t
Slide 35: Obesity Program Next Steps
Obesity Program Next Steps Treating general obesity & rare obesity indications Primary focus on hypothalamic obesity (HO) Development Timeline • MC4R agonists: o PL7737 oral (daily) small molecule o Long-acting peptide (weekly SC administration) • IND submissions planned 1H26 and mid-2026 • Phase 1
Slide 36: Spin-Out / Out-License Programs
Spin-Out / Out-License Programs
Slide 37: Spin-Out / Out-License Programs
Spin-Out / Out-License Programs Product/Indication R&D Phase 1 Phase 2 Phase 3 NDA Status/Next Steps Ocular Phase 3 MELODY-1 completed - positive data FDA confirmation on protocols and endpoints PL9643 MCR Agonist Phase 3 Melody-2 & -3 potential start 1H26 Dry eye disease (DED) Discussions Ongoing R
Slide 38: Ophthalmology MCR Programs
Ophthalmology MCR Programs • Proprietary Development for Retinal Disease Indications Research Collaboration / License Agreement with Boehringer Ingelheim August 2025 • Dry Eye Disease – PL9643
Slide 39: Melanocortin Agonists for Ophthalmic Disease
Melanocortin Agonists for Ophthalmic Disease Back of the eye (BOTE) Front of the eye (FOTE) Choroid Retinal Pigment Epithelium Conjunctiva Retinopathies Dry Eye Disease Retina Ocular Surface Cornea Corneal Protection Corneal Epithelium Trabecular Meshwork Optic Nerve Ciliary Body Glaucoma 1 39 1
Slide 40: Target markets and opportunities
Melanocortin Agonists for Ophthalmic Disease Target markets and opportunities Dry Eye Disease Glaucoma Global Market (2024 Est.) $7.0 Billion Global Market (2022 Act.) $8.03 Billion Global Market (2032 Est.) $12.3 Billion Global Market (2030 Est.) $11.52 Billion • Unsatisfied need for better tolerab
Slide 41: Boehringer Ingelheim retinal disease collaboration
Proprietary MCR Assets for the Treatment of Retinal Diseases Research Collaboration / License Agreement with Boehringer Ingelheim August 2025 Boehringer Ingelheim and Palatin to develop potential first-in-class • Upfront payment of €2.0 million melanocortin receptor targeted treatment for patients w
Slide 42: Dry Eye Overview
Dry Eye Overview Dry eye disease (DED) or keratoconjunctivitis is a multifactorial disorder of the tears and ocular surface Symptoms include dryness, irritation, redness, discharge and blurred vision Inflammation plays a prominent role in the development and amplification of the signs and symptoms o
Slide 43: PL9643 for Dry Eye Disease
PL9643 for Dry Eye Disease U.S. market value $1.65 billion1 Melanocortin agonism Resolves The Problem inflammation of • No effective chronic treatment that can provide rapid relief of dry eye corneal surface disease symptoms without tolerability issues Melanocortin Receptors present on The Opportuni
Slide 44: Patient Satisfaction is an Issue with Current Therapies
Patient Satisfaction is an Issue with Current Therapies Poor tolerability leads to high discontinuation rates Patients Receiving Rx for Dry Eye (48%)7 Response Rate Discontinuation Rate Response Rate Discontinuation Rate 64.4% 5,6,8 68-80%1-4 70.8% 5,6,8 Unknown Burning 72% Burning 64% Slow onset of
Slide 45: PL9643 Melody-1 Phase 3 Study Design
PL9643 Melody-1 Phase 3 Study Design 12-week, multicenter, 1:1 randomized, double-masked, vehicle-controlled adaptive design study Evaluate the efficacy and safety of PL9643 (575 patients enrolled) with moderate or severe dry eye disease defined as: Disease duration ≥ 5 years; Inferior Corneal Stain
Slide 46: Melody-1 Phase 3 clinical trial
PL9643 for Dry Eye Disease Melody-1 Phase 3 clinical trial Solves 3 recognized problems with current treatments: Efficacy, Onset Time to Effect, and Tolerability Broad Efficacy Across Multiple Signs and Symptoms • Co-Primary symptom endpoint of pain met statistical significance (P<0.025) • 7 of 11 S
Slide 47: Pain & Eye Dryness symptoms
PL9643 for Dry Eye Disease Pain & Eye Dryness symptoms: best-in-class symptom relief • Multiple symptom endpoints statistically significant including co-primary Pain endpoint • Rapid onset of efficacy at 2-weeks (earliest time point measured) • Continuous improvement over the 12 weeks of treatment •
Slide 48: MELODY-1 sign endpoint
PL9643 for Dry Eye Disease MELODY-1 sign endpoint • PL9643 separates from Vehicle at 2-weeks (earliest time point measured) and continues to improve over 12 weeks • Primary sign endpoint did not reach statistical significance • Fluorescein staining endpoints statistically significant ITT population
Slide 49: MELODY-1 symptom responder analysis
PL9643 for Dry Eye Disease MELODY-1 symptom responder analysis The First DED Therapy to Demonstrate Significant Clearing of Multiple Symptoms! ➢ For ALL symptoms PL9643 had a higher percentage of patients clearing symptoms ➢ 6 of 13 symptom endpoints were significant (p<0.05) in favor of PL9643 ➢ 2
Slide 50: Safety and ocular tolerability
PL9643 for Dry Eye Disease Safety and ocular tolerability PL9643` Phase 2 Study Phase 3 Study Ocular Adverse Events PL9643 Vehicle PL9643 Vehicle (N=80) (N=80) (N=287) (N=288) Phase 3 Melody-1 Study (n=575) Instillation Site Pain 0% 9% 3.1% 4.5% • PL9643 eye drop formulation was well-tolerated, Blur
Slide 51: Program summary / next steps
PL9643 for Dry Eye Disease Program summary / next steps Robust Phase 3 Program NDA Package & Target Filing • Three Efficacy/Long Term Safety Studies: • NDA File: Efficacy, Safety and CMC data o MELODY-1 (completed) • NDA File Date (Est.): 2H 2027 o MELODY-2 & -3 • FDA Approval/Launch (Est.): 2H 2028
Slide 52: Melanocortin Agonists for Ophthalmic Diseases Summary
Palatin Melanocortin Agonists for Ophthalmic Diseases Summary Novel differentiated products for ophthalmic indications Melanocortin MoA delivers efficacy with excellent safety & tolerability Proprietary compounds with long term IP estate Short, well defined, clinical pathways for regulatory approval
Slide 53: PL8177 Oral Formulation for Ulcerative Colitis
PL8177 Oral Formulation for Ulcerative Colitis
Slide 54: PL8177 Oral Formulation for Ulcerative Colitis
PL8177 Oral Formulation for Ulcerative Colitis Global ulcerative colitis (UC) market USD Phase 2 study evaluating safety and efficacy $5.5 billion 2021, projected to be $8 billion of PL8177-Oral in UC patients ongoing; by 2026 enrollment completed; topline data1Q 2025 MC1R on colon epithelial cells
Slide 55: UC patient treatment paradigm
PL8177 Oral Formulation for Ulcerative Colitis UC patient treatment paradigm Opportunity for PL8177 in Treating UC Indication Throughout the Treatment Paradigm Moderate Mild UC Moderate UC Severe UC 5-ASA (LialdaTM) Low 5-ASA PL8177 failure Drug Steroids enema/ suppository Price Steroids oral Steroi
Slide 56: Preclinical data rat DSS model
PL8177 Oral Formulation for Ulcerative Colitis Preclinical data rat DSS model total colitis index 50 ✱✱✱✱ ✱✱✱ 40 total colitis index 30 20 10 0 m bo 0u g kg a e g/ Sh ac 10 Pl 7 0m 17 30 8 e PL in am al es M Total colitis index Single nuclei RNAseq of DSS rat colon • Abnormalities of mucosal archite
Slide 57: PL8177-205 Phase 2 study design & timelines
PL8177 Oral Formulation for Ulcerative Colitis PL8177-205 Phase 2 study design & timelines Phase 2 RCT Parallel Group Study Using an Adaptive Design to Evaluate Safety, Tolerability and Efficacy 2022 2023 2024 2025 Patient Population PL8177 Oral UC Study Licensing • Adult patients with active PL8177
Slide 58: Topline data PL8177-205 Phase 2 UC study
C o n PL8177 Oral Formulation for Ulcerative Colitis f i Topline data PL8177-205 Phase 2 UC study d e n • Clinical Remission t i o Achieved in 33% of PL8177 treated subjects versus 0% on placebo after 8-weeks of treatment a • Clinical Response l o Achieved in 78% of PL8177 treated subjects versus 33
Slide 59: Target product profile for commercial success
PL8177 Oral Formulation for Ulcerative Colitis Target product profile for commercial success Preclinical Profile Oral Formulation PK Clinical • High potency at melanocortin receptors • Phase 1 radiolabeled micro-dose study • Phase 1 clinical SAD/MAD study with the 1 with the oral formulation, confir
Slide 60: Melanocortin Agonist for Diabetic Nephropathy
Melanocortin Agonist for Diabetic Nephropathy
Slide 61: Diabetic nephropathy and prevalence
Melanocortin Agonist for Diabetic Nephropathy Diabetic nephropathy (DN) is a severe microvascular Diabetes and DN prevalence complication of diabetes mellitus (DM) • It is the most common form of chronic kidney • ~ 30 million US patients have CKD secondary to disease (CKD) the combination of hyperte
Slide 62: Melanocortin agonists increase key kidney cell types in diabetic rats
Melanocortin Agonist for Diabetic Nephropathy Melanocortin agonists increase key kidney cell types in diabetic rats Cell Populations by snRNAseq* Podocyte Podocyte Density Density by Histopathology 45 ✱ ✱✱ Healthy 60 WT1+ cells/glomerular area 40 Diabetic Percent of Nuclei 35 Diabetic + 40 30 4 MC1R
Slide 63: BREAKOUT study in diabetic nephropathy
Melanocortin Agonist for Diabetic Nephropathy BREAKOUT study in diabetic nephropathy BREAKOUT Study Schema Primary Research Question • Proportion of subjects with a ≥50% reduction in UP/Cr Secondary Research Questions • Proportion of subjects that achieve a reduction in UP/Cr ratios of ≥ 30% from ba
Slide 64: Topline results – BREAKOUT Study
Melanocortin Agonist for Diabetic Nephropathy Topline results – BREAKOUT Study in Diabetic • Addition of Bremelanotide to maximum tolerated RAAS inhibition Results therapy • 57% of patients achieved a clinical response >30% o Resulted in positive and clinically reduction from baseline in UP/Cr benef
Slide 65: Financial / Cap Table Snapshot, Milestones Recap
Financial / Cap Table Snapshot Milestones Recap
Slide 66: Financial Snapshot / Cap Table
Financial Snapshot / Cap Table Financial Highlights as of September 30, 2025 Cash and Cash Equivalents $1.3 million* No debt * Does not include does not include $6.5 million milestone payment related to our Boehringer Ingelheim collaboration in October 2025 and the net proceeds from our underwritten
Slide 67: Milestones Recap
Milestones Recap Melanocortin System Development Programs Date Obesity - MC4R Agonists – Weight Loss (Maintenance) Phase 2 BMT-801 Clinical Study Bremelanotide + GLP-1 (proof-of-concept study only) – Positive Topline Data Reported Completed PL7737 MC4R Oral Small Molecule Agonist – IND Filing / SAD/
Slide 68: Thank You.
Thank You. & PALATIN
Palatin Technologies — Investor Presentation (November 2025) on 6ix